HGH
Lab-made growth hormone: a prescription medicine for hormone deficiency that athletes also use off-label to build muscle; banned in sport.
The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.

DETAILED OVERVIEW
What is HGH?
HGH is recombinant human growth hormone: a lab-made version of the hormone that the pituitary gland produces. As a prescription medicine it is approved to treat growth hormone deficiency, Turner syndrome, short stature of unknown cause and wasting linked to AIDS. Athletes also use it off-label for building muscle, recovery and fat loss; in competitive sport it is banned year-round.
Much of its effect is carried by IGF-1, a growth factor made in the liver. Prolonged use can cause acromegaly (enlargement of the hands, feet and jaw), thickening of the heart muscle and insulin resistance. Fluid retention, joint pain and carpal tunnel syndrome, which causes numbness in the hand, are common. It is contraindicated in active cancer and diabetes and should be avoided in pregnancy.
Mechanism
GH receptor agonist, IGF-1 elevator
Half-life
~3 hours (subcutaneous)
Onset
4-8 weeks (IGF-1 peak)
Legal status
USA: FDA Rx. HU/EU: Rx. WADA: banned.
HGH is an intricate peptide with effects more complex than commonly assumed. It can increase the conversion of T4 to reverse T3, lowering active thyroid output over time, so some users pair it with T4/T3 and monitor thyroid panels closely. It tends to raise fasting blood glucose and acutely reduce insulin sensitivity at higher doses, making carbohydrate and insulin dynamics important. Water retention is extremely common early on due to sodium retention and increased extracellular fluid. Numbness, tingling, or carpal-tunnel-like symptoms from fluid-driven nerve compression are also reported. HGH significantly raises IGF-1, which is responsible for most of the anabolic/recovery effects. Sleep can become more restorative, but exogenous GH can sometimes disrupt sleep in susceptible users. Exogenous use suppresses endogenous GH production, so a dose above natural output is typically required. Long-term effects may include improved collagen density but also potential organ growth at very high doses.
HGH is almost always administered subcutaneously, typically daily due to its short half-life. Pre-bed dosing in a fasted state (2-4 hours after the last meal) is commonly recommended since insulin directly opposes GH.
⚠ Not clinical evidence – based on user accounts.
Data console
Lab data
Pope HG Jr, Wood RI, Rogol A, Nyberg F, Bowers L, Bhasin S . Performance Enhancing Hormone Doping in Sport.. Endocr Rev.
Kerr HL, Krumm K, Myree N . Ghrelin Receptor Deletion or Pharmacological Inhibition Improves Muscle Function in Aging Male Mice.. Aging Cell.
Melmed S. . Acromegaly: clinical features and management. N Engl J Med. 2006;355(24):2558-2573..
Equey T, Pastor A, de la Torre Fornell R, Thuyne WV, Deventer K, Sottas PE . Application of the Athlete Biological Passport Approach to the Detection of Growth Hormone Doping.. J Clin Endocrinol Metab.
Safety
Side effects, stop signs, contraindications
Side effects · 8
- Insulin resistance and elevated fasting glucose: GH antagonises insulin and raises hepatic gluconeogenesis/glycogenolysis, pushing toward type 2 diabetes over time (rising HbA1c).
- Fluid retention and peripheral oedema: sodium and water retention, early and very common, especially above 4 IU/day (puffy face, ankle swelling).
- Carpal tunnel syndrome and paraesthesia: fluid-related nerve compression causes numbness, tingling and hand pain; usually reversible on dose reduction.
- Acromegalic changes with chronic/high-dose use: enlargement of hands, feet and jaw, coarsening facial features, organomegaly and arthralgia.
- Cardiac hypertrophy and cardiomegaly: long-term concentric left-ventricular hypertrophy and impaired contractile function, with the raised cardiovascular mortality seen in acromegaly.
- Thyroid shift: GH increases T4-to-reverse-T3 conversion and lowers active T3, potentially causing subclinical hypothyroidism (fatigue); rT3/fT3/fT4 monitoring is warranted.
- Arthralgia, myalgia and joint stiffness: common complaints, partly from fluid retention and partly from tissue growth.
- Theoretical tumour/growth-promoting risk: chronically high IGF-1 is mitogenic and may accelerate growth of an existing malignancy, hence contraindicated in active cancer.
Contraindications · 7
- Active malignancy or history of cancer: absolute contraindication due to the mitogenic effect of raised IGF-1.
- Diabetes, prediabetes or insulin resistance: GH is diabetogenic, worsening glycaemic control and potentially aggravating retinopathy.
- Acute critical illness (major surgery, multiple trauma, acute respiratory failure): high-dose somatropin increased mortality in ICU trials, contraindicated.
- Active proliferative or severe diabetic retinopathy: GH/IGF-1 signalling can drive progression.
- Overt heart failure, uncontrolled hypertension or pre-existing left-ventricular hypertrophy: fluid retention and myocardial growth can precipitate decompensation.
- Pregnancy and breastfeeding: avoided due to hormonal effects and glucose-metabolism disturbance; safety not established.
- Non-therapeutic (performance) use: the above risks are unmanageable without medical supervision; WADA-prohibited (category S2).
Related Performance Compounds
Same therapeutic category
Studies
Related research and clinical findings
Performance Enhancing Hormone Doping in Sport.
Pope HG Jr, Wood RI, Rogol A, Nyberg F, Bowers L, Bhasin S
Ghrelin Receptor Deletion or Pharmacological Inhibition Improves Muscle Function in Aging Male Mice.
Kerr HL, Krumm K, Myree N
Acromegaly: clinical features and management
Melmed S.
Application of the Athlete Biological Passport Approach to the Detection of Growth Hormone Doping.
Equey T, Pastor A, de la Torre Fornell R, Thuyne WV, Deventer K, Sottas PE
Telegram
Have a question about HGH?
Reach out to an advisor on Telegram. Performance compounds are presented with a harm-reduction approach, based on peer-reviewed evidence.
Personalized consultation
Want a detailed conversation tailored to your data?
Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.
Fill out the form~5–7 min · prep questionnaire · confidential · GDPR-compliant
The information here is for educational and scientific purposes only. Performance-enhancing compounds (AAS, prohormones, stimulants, doping agents) are illegal without prescription in Hungary and most of the EU, and carry serious health and legal risks. WADA bans them in competitive sport. This is NOT a usage guide, and we do not encourage any illegal use. If you do use them, medical supervision and regular bloodwork are ESSENTIAL. Severe endocrine, cardiovascular, hepatic and psychiatric side effects are possible.


